Why Immunogenicity Matters for Biologic Drugs
Biologic drugs, including monoclonal antibodies, fusion proteins, ADCs, and gene therapy vectors, are structurally complex molecules derived from biological systems. When administered to patients, they can trigger an immune response. The body may produce antibodies directed against the therapeutic molecule itself: anti-drug antibodies, or ADAs.
The clinical consequences of ADA development range from inconsequential to serious. At one end of the spectrum, low-titre ADAs may have no effect on drug pharmacokinetics or efficacy. At the other end, high-titre neutralising ADAs can accelerate drug clearance, abolish efficacy, and, in rare cases, trigger severe hypersensitivity reactions or cross-react with an endogenous protein. Regulators require a systematic immunogenicity assessment for all biologic drug programmes, and the data package must be in place before Phase I dosing begins.
The Tiered Immunogenicity Testing Strategy
The regulatory-recommended approach to immunogenicity testing uses a tiered strategy designed to balance sensitivity and specificity efficiently. The FDA’s guidance on immunogenicity testing for therapeutic protein products and the EMA’s guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins both describe this framework, and the ICH M10 bioanalytical method validation guideline provides the validation requirements applicable to immunogenicity assays.
| Tier | Assay Purpose | Acceptance Criterion | What Happens Next |
| Tier 1: Screening | Detect all potentially ADA-positive samples with high sensitivity | Cut-point set at approximately 5% false positive rate | Positive samples proceed to Tier 2 |
| Tier 2: Confirmatory | Confirm true positives by drug competition | Typically greater than 20-25% inhibition signals confirmation | Confirmed positives proceed to Tier 3 |
| Tier 3: Titration | Quantify ADA titre in confirmed positive samples | Serial dilution to endpoint | High-titre samples may proceed to neutralisation assay |
| Tier 4: Neutralisation | Determine whether ADAs block drug activity | Cell-based or competitive ligand-binding assay | Neutralising ADA data informs clinical risk assessment |
Cut-Point Setting: The Statistical Foundation of Immunogenicity Assays
The screening cut-point is the signal threshold above which a sample is classified as potentially ADA-positive. Setting this threshold correctly is critical: too low and you generate an unmanageable number of false positives that consume confirmatory assay capacity; too high and you miss true positive samples.
Cut-point setting uses a statistical approach based on the distribution of signal responses in a panel of drug-naive individuals from the target population. Typically a parametric or non-parametric approach is used to set the cut-point at a level corresponding to approximately a 5% false positive rate. The cut-point must be evaluated separately for each matrix used in the study, and a normalised or floating cut-point approach is commonly used to account for plate-to-plate variation.
Drug Tolerance: The Biggest Technical Challenge in ADA Assays
Drug tolerance refers to the ability of an immunogenicity assay to detect ADAs in the presence of circulating drug. This is a fundamental challenge because clinical samples collected during a dosing study will contain the therapeutic molecule, which can bind to any ADAs in the sample and prevent them from being detected by the assay. An assay with poor drug tolerance will produce false negative results in samples collected near Tmax, leading to underestimation of the true incidence of immunogenicity.
Strategies for improving drug tolerance include acid dissociation pre-treatment of samples to disrupt drug-ADA complexes before analysis, the use of assay formats with inherently higher drug tolerance such as bridging ELISA configurations, and the optimisation of sample dilution and blocking strategies. Drug tolerance is one of the key parameters evaluated during immunogenicity assay validation.
Immunogenicity Programme Design Considerations
Sample Collection Timing
Immunogenicity samples must be collected at pre-dose and at defined intervals throughout and after the dosing period. The timing of samples should reflect the expected time course of ADA induction: too few samples and you may miss the peak of the immune response; too many and you impose unnecessary burden on the clinical site and the patient.
Matrix Selection
Most immunogenicity assays use serum or plasma as the primary matrix. The choice between serum and plasma can affect assay performance because of differences in protein composition and the presence of clotting factors. The matrix used for assay development and validation must match the matrix collected in the clinical study.
Risk-Based Approach to Neutralisation Testing
Not all ADC or biologic programmes require a full four-tier immunogenicity programme including cell-based neutralisation assays. A risk-based approach, considering the target, the patient population, the dosing regimen, and the clinical consequences of neutralising ADAs, is used to determine which tiers are required and when neutralisation data is needed.
Ardena’s Immunogenicity Testing Services
Ardena’s bioanalytical team in Assen provides complete immunogenicity testing programmes for biologic drug development, including screening, confirmatory, titration, and neutralisation assays. The team is experienced in developing and validating assays on MSD ECL and ELISA platforms, applying appropriate cut-point setting methodologies, and producing validation reports that meet ICH M10 and agency-specific requirements.
Ardena offers integrated immunogenicity and PK bioanalysis, enabling the simultaneous characterisation of drug exposure and immune response data that is required for a complete safety and efficacy assessment.
